The ICU-ROX Trial
The ICU-ROX Trial will test the hypothesis that, compared to a liberal approach, a conservative approach to oxygen delivery may reduce lung collapse (atelectasis), decrease the risk of new non- respiratory organ dysfunction, and might reduce 28-day mortality.
The ICU-ROX Trial
Background
- More than 20,000 New Zealanders are admitted to an intensive care unit (ICU) annually. ICU patients are the sickest patients in the hospital and many require life support (mechanical ventilation).
- Although supplemental oxygen is universally delivered to patients who require mechanical ventilation in the ICU, there is no level I evidence with respect to the most appropriate ‘dose’ of oxygen to provide to these patients.
- It is generally accepted that abnormally low levels of oxygen should be avoided where possible; however, there is no consensus regarding the approach to abnormally high levels of oxygen in patients who require mechanical ventilation
Aims
Primary: To determine whether a conservative approach to oxygen therapy, which minimises unnecessary exposure to hyperoxaemia, will increase day 90 survival compared to a more liberal approach to oxygen therapy which does not specifically aim to avoid exposure to hyperoxaemia.
Methods
- the study is a multicentre, parallel group randomised controlled superiority trial which will allocate ICU patients in a 1:1 ratio to liberal or conservative oxygen therapy
- the study will compare two approaches to oxygen therapy in adults requiring mechanical ventilation in the ICU
- the study will be conducted in ICUs in Australia and New Zealand
Supported by the Health Research Council of New Zealand
Coordinating centre: The Medical Research Institute of New Zealand
Chief Investigator: Dr Paul Young, Specialist in Intensive Care Medicine, Wellington Hospital